Somalogic Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 36.3% | 33.1% | 40.4% | 43.9% | 45.5% | 50.7% | 50.0% | 28.0% | 68.9% | 60.4% | 54.6% | 52.8% | 58.8% | |
| 63.7% | 66.9% | 59.6% | 56.1% | 54.5% | 49.3% | 50.0% | 72.0% | 31.1% | 39.6% | 45.4% | 47.2% | 41.2% | |
| 26.8% | 43.0% | 43.4% | 78.0% | 48.7% | 60.1% | 124.7% | 46.6% | 120.0% | 69.0% | 52.8% | 47.4% | 70.9% | |
| – | 67.9% | 4.0% | 147.1% | 3.5% | 184.8% | 310.3% | 122.8% | 181.9% | 228.2% | 199.1% | 108.3% | 177.9% | |
| 62.7% | 111.0% | 118.4% | 181.2% | 177.8% | 194.1% | 385.0% | 169.4% | 320.5% | 236.8% | 197.3% | 155.7% | 224.3% | |
| 1.0% | -44.1% | -58.8% | -125.1% | -123.3% | -144.9% | -335.0% | -97.4% | -289.3% | -197.2% | -151.9% | -127.4% | -188.3% | |
| 31.0% | 6.2% | 0.7% | 0.0% | 0.6% | 127.5% | 172.5% | 16.9% | 312.5% | 29.4% | – | – | – | |
| -31.6% | -50.3% | -67.4% | -207.2% | -101.4% | -17.3% | -162.5% | -80.5% | -262.1% | -167.8% | -121.0% | -98.3% | -159.1% | |
| 32.6% | 6.2% | 8.6% | 82.1% | 0.2% | -127.5% | -172.5% | -1.5% | -0.5% | 0.0% | 0.0% | 2.2% | 0.5% | |
| -31.6% | -50.3% | -67.4% | -207.2% | -101.4% | 110.2% | 10.0% | -79.0% | -261.6% | -167.8% | -121.0% | -100.5% | -159.5% | |
| 2.0% | -40.3% | -63.3% | -204.5% | -99.7% | -144.0% | -328.2% | -88.8% | -265.0% | -188.6% | -145.3% | -82.5% | -166.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.